Last reviewed · How we verify

NG-Monomethyl-L-Arginine

VA Office of Research and Development · Phase 2 active Small molecule

NG-Monomethyl-L-Arginine is a Small molecule drug developed by VA Office of Research and Development. It is currently in Phase 2 development. Also known as: LNMMA, L-NMMA.

At a glance

Generic nameNG-Monomethyl-L-Arginine
Also known asLNMMA, L-NMMA
SponsorVA Office of Research and Development
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about NG-Monomethyl-L-Arginine

What is NG-Monomethyl-L-Arginine?

NG-Monomethyl-L-Arginine is a Small molecule drug developed by VA Office of Research and Development.

Who makes NG-Monomethyl-L-Arginine?

NG-Monomethyl-L-Arginine is developed by VA Office of Research and Development (see full VA Office of Research and Development pipeline at /company/va-office-of-research-and-development).

Is NG-Monomethyl-L-Arginine also known as anything else?

NG-Monomethyl-L-Arginine is also known as LNMMA, L-NMMA.

What development phase is NG-Monomethyl-L-Arginine in?

NG-Monomethyl-L-Arginine is in Phase 2.

Related